Q32 Bio Inc. (LON:0T6G)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 34.59M +9.6% |
| Revenue (ttm) | n/a |
| Net Income | -31.32M |
| EPS | -2.57 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 683 |
| Average Volume | 1,991 |
| Open | 4.000 |
| Previous Close | 3.560 |
| Day's Range | 3.580 - 4.000 |
| 52-Week Range | 1.320 - 6.170 |
| Beta | n/a |
| RSI | 52.12 |
| Earnings Date | Mar 12, 2026 |
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-0... [Read more]
News
Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB)
Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB)
Q32 Bio Sells Complement Inhibitor ADX-097 To Akebia Therapeutics
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the...
Dow Dips 200 Points; Q32 Bio Shares Jump
Q32 Bio Inc. (NASDAQ:QTTB) shares shot up 171% to $5.91 after the company sold its Phase 2 complement inhibitor ADX-097 to Akebia for $12 million upfront and potential milestone and royalty payments u...
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro . Q32 Bio on Mon...
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru...
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patien...
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bi...
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and o...
Q32 Bio (QTTB) Q2 Loss Drops 45%
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment...
Q32 Bio names interim chief medical officer
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. , ...
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD)...
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ...
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology...
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology ...
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-break...
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very se...
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata ...
Q32 Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis...
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; ...
Sio Capital Management, LLC Acquires Significant Stake in Q32 Bio Inc
Sio Capital Management, LLC Acquires Significant Stake in Q32 Bio Inc
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,...
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
On Wednesday, Q32 Bio Inc. (NASDAQ: QTTB) revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA) . The company plans to ex...